Authors of an article explored the evolving landscape of drug safety monitoring in the context of personalized treatments, focusing on the integration of pharmacogenetics to enhance drug safety. Genetic profiling is shown to aid in predicting drug responses and adverse reactions, highlighting the importance of phase 4 post-marketing surveillance due to the limitations of pre-marketing trials. The article also discusses the need for a comprehensive approach to drug safety, encompassing both pre-exposure risk management and post-exposure surveillance, while redefining pharmacoepidemiological methods.

The significance of integrating patient-specific genetic profiles into personalized medication leaflets and using advanced computational methods for data analysis is emphasized. Ethical, privacy, and data security challenges in precision medicine are also examined, stressing their implications for patient consent and data management. The article concludes that pharmacovigilance in the personalized medicine era must adapt to ensure drug safety is aligned with individual health needs. This requires utilizing advanced data collection and analysis methods, and addressing the unique challenges presented by precision medicine.

Reference: Silva L, Pacheco T, Araújo E, Duarte RJ, Ribeiro-Vaz I, Ferreira-da-Silva R. Unveiling the future: precision pharmacovigilance in the era of personalized medicine. Int J Clin Pharm. 2024;46(3):755-760. doi: 10.1007/s11096-024-01709-x.